|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2007-10-19
|
|
pubmed:abstractText |
Pertuzumab, a first-in-class human epidermal receptor 2 (HER2) dimerization inhibitor, is a humanized monoclonal anti-HER2 antibody that binds HER2's dimerization domain and inhibits HER2 signaling. Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/pertuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:DangThao PTP,
pubmed-author:DaviesAngela MAM,
pubmed-author:EberhardDavid ADA,
pubmed-author:GarlandLinda LLL,
pubmed-author:HerbstRoy SRS,
pubmed-author:JohnsonBruce EBE,
pubmed-author:LutzkerStuart GSG,
pubmed-author:LyonsBenjaminB,
pubmed-author:MelenevskyYuliaY,
pubmed-author:MendelsonDavidD,
pubmed-author:MillerVincent AVA,
pubmed-author:NataleRonald BRB,
pubmed-author:SchillerJoan HJH,
pubmed-author:Van den AbbeeleAnnick DAD,
pubmed-author:de VriesDaniel JDJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6175-81
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17947484-Adult,
pubmed-meshheading:17947484-Antibodies, Monoclonal,
pubmed-meshheading:17947484-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17947484-Antineoplastic Agents,
pubmed-meshheading:17947484-Biopsy,
pubmed-meshheading:17947484-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17947484-Dimerization,
pubmed-meshheading:17947484-Female,
pubmed-meshheading:17947484-Fluorodeoxyglucose F18,
pubmed-meshheading:17947484-Humans,
pubmed-meshheading:17947484-Lung Neoplasms,
pubmed-meshheading:17947484-Male,
pubmed-meshheading:17947484-Middle Aged,
pubmed-meshheading:17947484-Mutation,
pubmed-meshheading:17947484-Positron-Emission Tomography,
pubmed-meshheading:17947484-Protein Structure, Tertiary,
pubmed-meshheading:17947484-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17947484-Receptor, erbB-2,
pubmed-meshheading:17947484-Time Factors,
pubmed-meshheading:17947484-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
|
|
pubmed:affiliation |
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
